

(FILE 'HOME' ENTERED AT 15:15:36 ON 05 DEC 2006)

FILE 'REGISTRY' ENTERED AT 15:15:47 ON 05 DEC 2006

L1 STRUCTURE UPLOADED

L2 0 S L1

L3 2 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 15:16:31 ON 05 DEC 2006

L4 1 S L3

FILE 'USPATFULL' ENTERED AT 15:17:22 ON 05 DEC 2006

L5 1 S L3

FILE 'HOME' ENTERED AT 15:15:36 ON 05 DEC 2006

=>

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n) :

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:15:47 ON 05 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 DEC 2006 HIGHEST RN 914768-89-1

DICTIONARY FILE UPDATES: 4 DEC 2006 HIGHEST RN 914768-89-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>


Uploading C:\Program Files\Stnexp\Queries\10659091amended.str

L1 STRUCTURE uploaded

=> d 11

L1 HAS NO ANSWERS

L1 STR



$\text{G}_1 \text{ O, S}$
 $\text{G}_2 \text{ H, Ak}$
 $\text{G}_3 \text{ O, N}$

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 15:16:05 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED 1 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1 TO 80
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 15:16:10 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 10 TO ITERATE


100.0% PROCESSED 10 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

L3 2 SEA SSS FUL L1

=> d l3 scan

L3 2 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 5-Heptenoic acid, 7-[(1R,2S,3R,5R)-2-[[[[(butylamino)carbonyl]oxy]methyl]-5-chloro-3-hydroxycyclopentyl]-; (5Z)- (9CI)
MF C18 H30 Cl N O5

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 2 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 5-Heptenoic acid, 7-[(1R,2S,3R,5R)-2-[[[(butylamino)carbonyl]oxy]methyl]-5-
 chloro-3-hydroxycyclopentyl]-, methyl ester, (5Z)- (9CI)
 MF C19 H32 Cl N O5

Absolute stereochemistry.
 Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus			
COST IN U.S. DOLLARS	SINCE FILE	TOTAL	
FULL ESTIMATED COST	ENTRY	SESSION	
	166.94	167.15	

FILE 'CAPLUS' ENTERED AT 15:16:31 ON 05 DEC 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Dec 2006 VOL 145 ISS 24
FILE LAST UPDATED: 4 Dec 2006 (20061204/ED)


Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13
L4 1 L3

=> d 14 ti abs bib

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of 2-(thiocarbamoyloxy)- and 2-(carbamoyloxy)cyclopentane-1-heptan(en)oic acid compounds for treating ocular hypertension
GI



AB A method of treating ocular hypertension (glaucoma) comprises administering to a mammal having ocular hypertension a therapeutically effective amount of a compound represented by formula (I) [wherein a wavy segments indicate either the α or β configuration; the dashed bond represents a double bond or a single bond; U = :O, α - or β -halo; Z = O, S; Ar = (un)substituted C4-10 aryl or heteroaryl; n = 0-4; x, y = 0, 1; provided that when x is 1, yr is 0 and when x is 0, yr is 1; R1 = H, (un)substituted C \leq 6 alkyl; X = OR1, N(R1)2; Y = :O or represents 2 hydrogen radicals] or pharmaceutically acceptable salts and/or esters thereof. Thus, carbamoylation of (Z)-7-[(1R,2S,3R,5S)-2-(hydroxymethyl)-3,5-bis(tetrahydropyran-2-yloxy)cyclopentyl]hept-5-enoic acid Me ester with Bu isocyanate in the presence of DABCO in THF followed by treatment with pyridinium p-toluenesulfonate in MeOH gave (Z)-7-[(1R,2S,3R,5S)-2-[(butylcarbamoyloxy)methyl]-3,5-dihydroxycyclopentyl]hept-5-enoic acid Me ester which was silylated with tert-butyldimethylsilyl chloride in the presence of Et3N and 4-dimethylaminopyridine in CH2Cl2 to give (Z)-7-[(1R,2S,3R,5S)-2-[(butylcarbamoyloxy)methyl]-3-(tert-butyldimethylsilyloxy)-5-hydroxycyclopentyl]hept-5-enoic acid Me ester (II). Oxidation of II with tetrapropylammonium perruthenate, 4-methylmorpholine N-oxide, and 4Å

mol. sieves in CH₂C₁₂ to give (Z)-7-[(1R,2S,3R)-2-[(butylcarbamoyloxy)methyl]-3-(tert-butyldimethylsilyloxy)-5-oxocyclopentyl]hept-5-enoic acid Me ester which was treated with HF-pyridine in MeCN to give (Z)-7-[(1R,2S,3R)-2-[(butylcarbamoyloxy)methyl]-3-hydroxy-5-oxocyclopentyl]hept-5-enoic acid Me ester (III).

AN 2005:220145 CAPLUS

DN 142:297917

TI Preparation of 2-(thiocarbamoyloxy)- and 2-(carbamoyloxy)cyclopentane-1-heptan(en)oic acid compounds for treating ocular hypertension

IN Old, David W.; Burk, Robert M.

PA Allergan, Inc., USA

SO U.S. Pat. Appl. Publ., 12 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005054689 AU 2004272524 CA 2537794 WO 2005026109	A1 A1 AA A1	20050310 20050324 20050324 20050324	US 2003-659091 AU 2004-272524 CA 2004-2537794 WO 2004-US27001	20030909 20040818 20040818 20040818
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1663961	A1	20060607	EP 2004-781645	20040818
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004013722	A	20061017	BR 2004-13722	20040818
PRAI	US 2003-659091 WO 2004-US27001	A W	20030909 20040818		
OS	CASREACT 142:297917; MARPAT 142:297917				

=> file uspatfull

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE
ENTRY

TOTAL
SESSION

3.20 170.35

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE
ENTRY

TOTAL
SESSION

CA SUBSCRIBER PRICE

-0.75 -0.75

FILE 'USPATFULL' ENTERED AT 15:17:22 ON 05 DEC 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 30 Nov 2006 (20061130/PD)

FILE LAST UPDATED: 30 Nov 2006 (20061130/ED)

HIGHEST GRANTED PATENT NUMBER: US7143445

HIGHEST APPLICATION PUBLICATION NUMBER: US2006272066

CA INDEXING IS CURRENT THROUGH 28 Nov 2006 (20061128/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 30 Nov 2006 (20061130/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2006

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2006

=> s 13
LS 1 L3
=> d 15 ti abs bib

LS ANSWER 1 OF 1 USPATFULL on STN
TI Cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents
AB The invention relates to the use of cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and carbamoyloxy as therapeutic agents e.g. as ocular hypotensives. The compounds used in accordance with the invention are represented by the following formula I: ##STR1##

wherein a wavy segments indicate either the alpha (α) or beta (β) configuration; the dashed bond represents a double bond or a single bond; U, Y, X, R.sup.1, Ar, n, x and y are as defined in the specification.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2005:63647 USPATFULL
TI Cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents
IN Old, David W., Irvine, CA, UNITED STATES
Burk, Robert M., Laguna Beach, CA, UNITED STATES
PA Allergan, Inc. (U.S. corporation)
PI US 2005054689 A1 20050310
AI US 2003-659091 A1 20030909 (10)
DT Utility
FS APPLICATION
LREP Robert J. Baran (T2-7H), ALLERGAN, INC., Legal Department, 2525 Dupont Drive, Irvine, CA, 92612
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 645
CAS INDEXING IS AVAILABLE FOR THIS PATENT.